CMV Viremia is associated with a decreased incidence of BKV reactivation after kidney and kidney-pancreas transplantation

• Published in: Transplantation Vol. 96; no. 12; p. 1097
• Main Authors: Elfadawy, Nissreen, Flechner, Stuart M, Liu, Xiaobo, Schold, Jesse, Srinivas, Titte R, Poggio, Emilio, Fatica, Richard, Avery, Robin, Mossad, Sherif B
• Format: Journal Article
• Language: English
• Published: United States 27.12.2013
• Subjects: Adolescent; Adult; Aged; BK Virus - physiology; Cytomegalovirus - physiology; Cytomegalovirus Infections - blood; Female; Humans; Immunosuppressive Agents - therapeutic use; Incidence; Kidney Transplantation - methods; Male; Middle Aged; Multivariate Analysis; Pancreas Transplantation - methods; Pancreatic Diseases - therapy; Pancreatic Diseases - virology; Polymerase Chain Reaction; Polyomavirus Infections - blood; Prospective Studies; Renal Insufficiency - therapy; Renal Insufficiency - virology; Risk Factors; Treatment Outcome; Tumor Virus Infections - blood; Viremia - diagnosis; Virus Activation; Young Adult
• ISSN: 1534-6080
• DOI: 10.1097/TP.0b013e3182a6890d

Cytomegalovirus (CMV) and BK virus (BKV) infections can cause significant morbidity after kidney and kidney-pancreas transplant. There are limited data on the epidemiology and interactions between these two viral pathogens. We prospectively screened 609 kidney or kidney-pancreas transplant recipients from January 2007 to June 2011 for BKV and/or CMV viremia. This included 7453 quantitative BKV polymerase chain reaction and 15,496 quantitative CMV polymerase chain reaction tests. We evaluated risk factors and timing of these infections and the impact of treatment of one infection on the other. Among 609 recipients, 108 (17.7%) developed CMV viremia, of which 95 (88%) were asymptomatic, 5 (5%) had CMV syndrome, and 8 (7%) developed CMV tissue invasive disease at a median of 5.6 months after transplantation. Risk factors for CMV infection using multivariable analysis were D+R- serogroup (P≤0.0001), donor age >50 years (P=0.013), and higher mean tacrolimus (P=0.0009) and mycophenolate mofetil (P=0.01) blood levels. The incidence of BKV infection in the total population was 163 of 609 (26.7%), of which 150 (92%) occurred in patents without antecedent CMV viremia. Such patients demonstrated a higher rate of subsequent BKV viremia than patients with antecedent CMV viremia (P=0.003; hazard ratio, 2.05; 95% confidence interval, 1.2-3.4). Moreover, we found that only symptomatic CMV viremia had a significant negative impact on graft survival when compared with asymptomatic CMV viremia and those without CMV viremia (relative risk, 3.5; 95% confidence interval, 1.06-8.9; P=0.04). CMV viremia may indirectly protect against subsequent BK viremia possibly due to a reduction of intensity of immunosuppression after diagnosis of CMV viremia.